Evogene Ltd. (TLV:EVGN)

Market Cap	23.91M -35.7%
Revenue (ttm)	26.54M +7.2%
Net Income	-9.10M
EPS	-1.23
Shares Out	8.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,851
Average Volume	100,542
Open	280.00
Previous Close	285.70
Day's Range	272.60 - 280.00
52-Week Range	272.60 - 1,085.00
Beta	1.17
RSI	34.00
Earnings Date	Mar 5, 2026

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 117
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: EVGN

Financial Performance

In 2024, Evogene's revenue was $8.51 million, an increase of 50.90% compared to the previous year's $5.64 million. Losses were -$16.49 million, -30.96% less than in 2023.

Financial numbers in USD